Logo image of ADPT

ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock Fundamental Analysis

NASDAQ:ADPT - Nasdaq - US00650F1093 - Common Stock - Currency: USD

8.27  -0.06 (-0.72%)

After market: 8.27 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADPT. ADPT was compared to 57 industry peers in the Life Sciences Tools & Services industry. ADPT may be in some trouble as it scores bad on both profitability and health. ADPT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADPT has reported negative net income.
ADPT had a negative operating cash flow in the past year.
ADPT had negative earnings in each of the past 5 years.
In the past 5 years ADPT always reported negative operating cash flow.
ADPT Yearly Net Income VS EBIT VS OCF VS FCFADPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

ADPT has a worse Return On Assets (-34.96%) than 75.44% of its industry peers.
The Return On Equity of ADPT (-87.25%) is worse than 82.46% of its industry peers.
Industry RankSector Rank
ROA -34.96%
ROE -87.25%
ROIC N/A
ROA(3y)-29%
ROA(5y)-24.51%
ROE(3y)-64.95%
ROE(5y)-49.77%
ROIC(3y)N/A
ROIC(5y)N/A
ADPT Yearly ROA, ROE, ROICADPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

Looking at the Gross Margin, with a value of 58.46%, ADPT belongs to the top of the industry, outperforming 80.70% of the companies in the same industry.
In the last couple of years the Gross Margin of ADPT has declined.
The Profit Margin and Operating Margin are not available for ADPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.26%
GM growth 5Y-4.14%
ADPT Yearly Profit, Operating, Gross MarginsADPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

ADPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADPT has more shares outstanding than it did 1 year ago.
ADPT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ADPT has a worse debt to assets ratio.
ADPT Yearly Shares OutstandingADPT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
ADPT Yearly Total Debt VS Total AssetsADPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -1.17, we must say that ADPT is in the distress zone and has some risk of bankruptcy.
ADPT has a Altman-Z score of -1.17. This is in the lower half of the industry: ADPT underperforms 75.44% of its industry peers.
ADPT has a Debt/Equity ratio of 0.59. This is a neutral value indicating ADPT is somewhat dependend on debt financing.
ADPT has a worse Debt to Equity ratio (0.59) than 68.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF N/A
Altman-Z -1.17
ROIC/WACCN/A
WACC11.57%
ADPT Yearly LT Debt VS Equity VS FCFADPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.52 indicates that ADPT has no problem at all paying its short term obligations.
ADPT's Current ratio of 3.52 is in line compared to the rest of the industry. ADPT outperforms 56.14% of its industry peers.
A Quick Ratio of 3.38 indicates that ADPT has no problem at all paying its short term obligations.
ADPT has a Quick ratio of 3.38. This is in the better half of the industry: ADPT outperforms 61.40% of its industry peers.
Industry RankSector Rank
Current Ratio 3.52
Quick Ratio 3.38
ADPT Yearly Current Assets VS Current LiabilitesADPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.01% over the past year.
ADPT shows a small growth in Revenue. In the last year, the Revenue has grown by 5.09%.
ADPT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.03% yearly.
EPS 1Y (TTM)21.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.33%
Revenue 1Y (TTM)5.09%
Revenue growth 3Y5.07%
Revenue growth 5Y16.03%
Sales Q2Q%3.66%

3.2 Future

ADPT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.24% yearly.
Based on estimates for the next years, ADPT will show a very strong growth in Revenue. The Revenue will grow by 22.06% on average per year.
EPS Next Y13.11%
EPS Next 2Y16.37%
EPS Next 3Y17.24%
EPS Next 5YN/A
Revenue Next Year19.16%
Revenue Next 2Y20.47%
Revenue Next 3Y22.06%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ADPT Yearly Revenue VS EstimatesADPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
ADPT Yearly EPS VS EstimatesADPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADPT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADPT Price Earnings VS Forward Price EarningsADPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADPT Per share dataADPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ADPT's earnings are expected to grow with 17.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.37%
EPS Next 3Y17.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAPTIVE BIOTECHNOLOGIES

NASDAQ:ADPT (2/21/2025, 8:00:03 PM)

After market: 8.27 0 (0%)

8.27

-0.06 (-0.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-11 2025-02-11/amc
Earnings (Next)05-05 2025-05-05/amc
Inst Owners94.45%
Inst Owner Change0.35%
Ins Owners2.19%
Ins Owner Change-0.21%
Market Cap1.22B
Analysts81.43
Price Target9.18 (11%)
Short Float %5.91%
Short Ratio6.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.96%
Min EPS beat(2)8.94%
Max EPS beat(2)24.98%
EPS beat(4)4
Avg EPS beat(4)12.59%
Min EPS beat(4)5.24%
Max EPS beat(4)24.98%
EPS beat(8)6
Avg EPS beat(8)9.06%
EPS beat(12)10
Avg EPS beat(12)9.77%
EPS beat(16)13
Avg EPS beat(16)10.23%
Revenue beat(2)2
Avg Revenue beat(2)11.37%
Min Revenue beat(2)9.51%
Max Revenue beat(2)13.22%
Revenue beat(4)3
Avg Revenue beat(4)5.3%
Min Revenue beat(4)-7.37%
Max Revenue beat(4)13.22%
Revenue beat(8)5
Avg Revenue beat(8)1.72%
Revenue beat(12)8
Avg Revenue beat(12)1.22%
Revenue beat(16)12
Avg Revenue beat(16)5.43%
PT rev (1m)0%
PT rev (3m)3.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.09%
EPS NY rev (1m)0%
EPS NY rev (3m)6.99%
Revenue NQ rev (1m)-0.22%
Revenue NQ rev (3m)-0.66%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)2.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.89
P/FCF N/A
P/OCF N/A
P/B 5.46
P/tB 12.11
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS1.2
BVpS1.51
TBVpS0.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.96%
ROE -87.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.46%
FCFM N/A
ROA(3y)-29%
ROA(5y)-24.51%
ROE(3y)-64.95%
ROE(5y)-49.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.26%
GM growth 5Y-4.14%
F-Score2
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.24%
Cap/Sales 2.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.52
Quick Ratio 3.38
Altman-Z -1.17
F-Score2
WACC11.57%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.33%
EPS Next Y13.11%
EPS Next 2Y16.37%
EPS Next 3Y17.24%
EPS Next 5YN/A
Revenue 1Y (TTM)5.09%
Revenue growth 3Y5.07%
Revenue growth 5Y16.03%
Sales Q2Q%3.66%
Revenue Next Year19.16%
Revenue Next 2Y20.47%
Revenue Next 3Y22.06%
Revenue Next 5YN/A
EBIT growth 1Y14.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.86%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.21%
OCF growth 3YN/A
OCF growth 5YN/A